Citi Starts MacroGenics (MGNX) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Oppenheimer Remains Bullish on Macrogenics (MGNX) Following Announced Entrance into NIAID Contract
September 18, 2015 10:54 AM EDTOppenheimer reiterated an Outperform rating and $48.00 price target on MacroGenics (NASDAQ: MGNX) following the announced entrance into a contract with the National Institute of Allergy and Infectious Diseases (NIAID) for the development of DARTs products for the treatment of HIV. NIAID will pay... More
